The FOXC2 Transcription Factor: A Master Regulator of Chemoresistance in Cancer
FOXC2, a member of the forkhead box family of transcription factors, is an emerging oncogene that has been linked to several hallmarks of cancer progression. Among its many oncogenic functions is the promotion of drug resistance, with evidence supporting roles for FOXC2 in escape from broad classes...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-02-01
|
| Series: | Technology in Cancer Research & Treatment |
| Online Access: | https://doi.org/10.1177/15330338231155284 |
| _version_ | 1797855311085699072 |
|---|---|
| author | Kristian M. Hargadon PhD Elijah W. Strong BS |
| author_facet | Kristian M. Hargadon PhD Elijah W. Strong BS |
| author_sort | Kristian M. Hargadon PhD |
| collection | DOAJ |
| description | FOXC2, a member of the forkhead box family of transcription factors, is an emerging oncogene that has been linked to several hallmarks of cancer progression. Among its many oncogenic functions is the promotion of drug resistance, with evidence supporting roles for FOXC2 in escape from broad classes of chemotherapeutics across an array of cancer types. In this Mini-Review, we highlight the current understanding of the mechanisms by which FOXC2 drives cancer chemoresistance, including its roles in the promotion of epithelial-mesenchymal transition, induction of multidrug transporters, activation of the oxidative stress response, and deregulation of cell survival signaling pathways. We discuss the clinical implications of these findings, including strategies for modulating FOXC2-associated chemoresistance in cancer. Particular attention is given to ways in which FOXC2 and its downstream gene products and pathways can be targeted to restore chemosensitivity in cancer cells. In addition, the utility of FOXC2 expression as a predictor of patient response to chemotherapy is also highlighted, with emphasis on the value of FOXC2 as a novel biomarker that can be used to guide therapeutic choice towards regimens most likely to achieve clinical benefit during frontline therapy. |
| first_indexed | 2024-04-09T20:21:38Z |
| format | Article |
| id | doaj.art-0d9c0734c8f24280baa9ddcaacf847f3 |
| institution | Directory Open Access Journal |
| issn | 1533-0338 |
| language | English |
| last_indexed | 2024-04-09T20:21:38Z |
| publishDate | 2023-02-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Technology in Cancer Research & Treatment |
| spelling | doaj.art-0d9c0734c8f24280baa9ddcaacf847f32023-03-30T23:33:34ZengSAGE PublishingTechnology in Cancer Research & Treatment1533-03382023-02-012210.1177/15330338231155284The FOXC2 Transcription Factor: A Master Regulator of Chemoresistance in CancerKristian M. Hargadon PhDElijah W. Strong BSFOXC2, a member of the forkhead box family of transcription factors, is an emerging oncogene that has been linked to several hallmarks of cancer progression. Among its many oncogenic functions is the promotion of drug resistance, with evidence supporting roles for FOXC2 in escape from broad classes of chemotherapeutics across an array of cancer types. In this Mini-Review, we highlight the current understanding of the mechanisms by which FOXC2 drives cancer chemoresistance, including its roles in the promotion of epithelial-mesenchymal transition, induction of multidrug transporters, activation of the oxidative stress response, and deregulation of cell survival signaling pathways. We discuss the clinical implications of these findings, including strategies for modulating FOXC2-associated chemoresistance in cancer. Particular attention is given to ways in which FOXC2 and its downstream gene products and pathways can be targeted to restore chemosensitivity in cancer cells. In addition, the utility of FOXC2 expression as a predictor of patient response to chemotherapy is also highlighted, with emphasis on the value of FOXC2 as a novel biomarker that can be used to guide therapeutic choice towards regimens most likely to achieve clinical benefit during frontline therapy.https://doi.org/10.1177/15330338231155284 |
| spellingShingle | Kristian M. Hargadon PhD Elijah W. Strong BS The FOXC2 Transcription Factor: A Master Regulator of Chemoresistance in Cancer Technology in Cancer Research & Treatment |
| title | The FOXC2 Transcription Factor: A Master Regulator of Chemoresistance in Cancer |
| title_full | The FOXC2 Transcription Factor: A Master Regulator of Chemoresistance in Cancer |
| title_fullStr | The FOXC2 Transcription Factor: A Master Regulator of Chemoresistance in Cancer |
| title_full_unstemmed | The FOXC2 Transcription Factor: A Master Regulator of Chemoresistance in Cancer |
| title_short | The FOXC2 Transcription Factor: A Master Regulator of Chemoresistance in Cancer |
| title_sort | foxc2 transcription factor a master regulator of chemoresistance in cancer |
| url | https://doi.org/10.1177/15330338231155284 |
| work_keys_str_mv | AT kristianmhargadonphd thefoxc2transcriptionfactoramasterregulatorofchemoresistanceincancer AT elijahwstrongbs thefoxc2transcriptionfactoramasterregulatorofchemoresistanceincancer AT kristianmhargadonphd foxc2transcriptionfactoramasterregulatorofchemoresistanceincancer AT elijahwstrongbs foxc2transcriptionfactoramasterregulatorofchemoresistanceincancer |